Co‐occurrence of JAK2 V617F‐mutated essential thrombocythemia and chronic lymphocytic leukemia harboring der(8;17)(q10;q10)

BACKGROUND AND CASE: We herein present a case of the co‐occurrence of JAK2‐mutated essential thrombocythemia (ET) with chronic lymphocytic leukemia (CLL) harboring the recurrent and rare whole‐arm translocation, der(8;17)(q10;q10). The co‐existence of lymphoproliferative neoplasms and myeloprolifera...

Descripción completa

Detalles Bibliográficos
Autores principales: Manabe, Masahiro, Tanizawa, Nao, Nanno, Satoru, Hagiwara, Yuuji, Asada, Reiko, Koh, Ki‐Ryang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575505/
https://www.ncbi.nlm.nih.gov/pubmed/35715969
http://dx.doi.org/10.1002/cnr2.1658
Descripción
Sumario:BACKGROUND AND CASE: We herein present a case of the co‐occurrence of JAK2‐mutated essential thrombocythemia (ET) with chronic lymphocytic leukemia (CLL) harboring the recurrent and rare whole‐arm translocation, der(8;17)(q10;q10). The co‐existence of lymphoproliferative neoplasms and myeloproliferative neoplasms is suggested to be a rare event. Under this condition, the lymphoproliferative disorder presents a clinically indolent course with a low‐risk biological profile. However, the present case showed aggressive disease progression, reflecting a poor prognostic factor; that is, the loss of 17p caused by the whole‐arm der(8;17)(q10;q10) translocation. CONCLUSION: The present case report emphasizes the importance of considering the involvement of a genetically poor prognostic factor, regardless of the co‐occurrence of CLL and ET.

Ejemplares similares